Does the culture here differ by division

Discussion in 'Sunovion' started by Anonymous, Jan 10, 2015 at 2:08 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Curious if each division differs with cultures or are they all the same? Please do share.
     

  2. Anonymous

    Anonymous Guest

    yes. there are differences - ie on the Latuda side there has been success with the drug, see the overall sales numbers, many long time employees but overall unhappiness with the comp plan. In the past there was good leadership, many of whom are now leaving.

    on the Aptiom side, there is a bad product, terrible launch preparation, inexperienced management, bad marketing materials- ask the FDA, poor managed care, vacancies, inconsistent goals, a bad comp plan - dare to hit goal in a quarter and you will be beaten into submission the next, promotion of people who have been failures and a surprisingly resiliant sales team who perseveres due to high base salaries.
     
  3. Anonymous

    Anonymous Guest

    What is the pay range for vacant Aption territories?
     
  4. Anonymous

    Anonymous Guest

    0-130,000 This is a high priced contract sales position. The drug is licensed to Sunovion by Bial. Aptiom has been a miserable failure in Europe for 5 years and is now a failure in the US. The US physicians are no less smart than their European counterparts.

    The drug is basically viewed by physicians as a high priced generic. There are minute differences between generic Trileptal and Aptiom but none that warrant the cost to the patient or the step edits and prior authorizations that physicians are unwilling to complete.

    Goals are unobtainable and there is little potential to make money despite launch mode. If you happen to make the 7500 goal, your goal for the next quarter will be an unreachable level

    Sales organization is on borrowed time. Take the job if you are unemployed. Otherwise keep looking.
     
  5. Anonymous

    Anonymous Guest

    Things will soon be changing on the Aptiom side of the house. They are finally going to hold the sales team accountable. Management very upset about call metrics. Many terrirories are only averaging 4 physician interactions per day. I've heard they are going to put the screws to the reps and finally start to chop those that are just faking it and collecting the high base salary. I've also heard they are going to bring in new reps for an expansion and give them lower base so they get ones hungry to sell. That would be a refreshing change. Many are hardly working and openly say they don't need to make much bonus because they were brought on board with huge increases in base pay from their previous jobs. As an Aptiom specialist who actually works full days I can tell you that this will be a welcome change. We have some really bad RBM's that were nothing more than glorified reps at other co's and were hired here to be RBM's. They are horrible and must be removed from their positions. They don't hold their reps accountable and can not motivate or help us properly target and coach us. Who hired these bozo's? That has to change if this ship is to be righted.

    One last thing also, managed markets will be contracting heavily for Aptiom this year. At the top levels of the organization they have finally realized that this class is no longer open and a top priority will be to contract Aptiom in every single plan where Vimpat is in a better formulary position.

    Won't that be a refreshing change?! I'm so sick of them telling us that we have the same access as Vimpat when we don't!! Managed markets doing their job and contracting it will be a good start if we have any chance to turn this product around and have a chance of keeping our jobs!
     
  6. Anonymous

    Anonymous Guest

    Come on pal, call metrics really? You sound like an old Pfizer or Merck clone from yesteryear. Frequency and mass marketing does not sell a damn thing in Pharma especially with a nitche product like Aptiom. You can make 12 calls a day and it won't matter. Ever hear of the old 80/20 rule? Well with Aptiom it's more like the 95/5 rule. 95% of your bizz will come from 5% of your docs with Aptiom and that's a fact! Save the crap pal on your increased metric crap.
     
  7. Anonymous

    Anonymous Guest

    what will not change in the future is Aptiom. At this point the drug will not have wide usage. The primary market is epileptologists. In many cases Aptiom is 3rd or 4th line. This is by physician choice and as a result of poor managed care. As an example there are many times step edits where generic tegretol and generic trileptal must fail before they will approve Aptiom. In those instances Aptiom will not be used or will be setup for failure.

    Management is attempting to use sales tactics that were successful in the 1990s, dinner programs and new poor tactics web conferences, open galleries. The drug has now been in the US for 9 months. I see most of my targets weekly and other targets bi-weekly. They will not write this drug. This is the norm as most territories have very few writers.

    Blame the reps time has come. In sports you fire the coach and not the whole team. Here we will begin taking out the team and leave the same ineffective management.

    It is not better openers or closings. It is not making an extra .2 calls per day. It is not seening my top targets more than once a week. The MDs get it. I have seen some targets 36 times since launch and others 18 times. They simply see little need for this drug. That being said yes change the reps and then change them again and again and again. By the time that the physician sees the 2nd and 3rd reps in a territory selling Aptiom it will confirm what they already think about Sunovion and Aptiom. and yes bring in less experienced reps in the 70-90,000 ranges as that will also make a statement.

    So blame the lazy, incompetent reps for the failure of Aptiom you know all of the reps that you carefully interviewed and hired to launch this dog of a drug.
     
  8. Anonymous

    Anonymous Guest

    Latina culture was great up unail the time that GMAN took for granted that the sales force built that success. It's funny how success can go to one's head and in particular Sunovion. SR leadership has taken success for granted and assumed that Latuda has such momentum that the sales would continue to come in regardless of who is selling or leading in the field. This has bred arrogance and in turn an exodus which is only beginning. Too bad because it was good while it lasted.
     
  9. Anonymous

    Anonymous Guest

    Brovana..underperforming...HHC determines it's success. Now Brovana being trained on Aptiom to help that underperforming launch. Latuda performing but soon to be underperforming with leadership decisions and mass exodus...not to mention Abilify generic in a couple of months.
     
  10. Anonymous

    Anonymous Guest

    this is exactly how it will play out. enough said. get out now. u r nuts if u r not looking. u owe it to yourself and family. management will try to make you feel like a failure. don't believe that for one moment. good luck to all reps. as I should be gone by 2 weeks time.
     
  11. Anonymous

    Anonymous Guest

    Well, since Gish is now over all the divisions, it's safe to say the culture is the same. Horrible! Good people leaving quickly. At least the others not selling Latuda will get to hear how funny the G-man is. His singing is also amazing. What the heck has happened to this place?
     
  12. Anonymous

    Anonymous Guest

    As a Brovana rep, our division was already in a bad place. Putting Gish in charge takes us to a new low. God helps us all!
     
  13. Anonymous

    Anonymous Guest

    Success (or lack thereof) will determine DFs promotion to CCO. Nuff said.
     
  14. Anonymous

    Anonymous Guest

     
  15. Anonymous

    Anonymous Guest

    Karyoke is big in Japan.

    G-man